• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gelteq wins U.S. patent for gel-based blood glucose testing platform

September 13, 2021 By Sean Whooley

GelteqGelteq announced today that it received a U.S. patent for its GTT Gel product for testing human response to oral glucose loads.

Melbourne, Australia-based Gelteq designed its GTT Gel diabetes diagnostic system for use in pathology labs and at-home testing through a proprietary gel-based delivery system.

The tests take blood samples from patients at different time intervals (ranging from zero to two hours after drinking a measured dose of a glucose solution) to detect diabetes, insulin resistance or other disorders of glucose metabolism.

Based on Gelteq’s technology that can “gelify” a wide range of ingredients to create an easily ingestible formulation for many applications, the platform can offer benefits for diabetes diagnostic testing, including masking the strong sugar taste of test ingredients, reducing the volume needed to be consumed, creating a more accurate dosage and supporting better absorption in the gastrointestinal system.

Gelteq said in a news release that it plans to launch a mobile diabetes screening kit in the U.S. in the first quarter of 2022, making it available to hospitals, labs, medical centers and pharmacies around the country.

“This U.S. patent provides strong protection for our revolutionary gel technology and our highly differentiated gel science, particularly for the critical field of diabetes testing,” Gelteq CEO Nathan Givoni said in the release. “Early diagnosis of prediabetes or diabetes is crucial for the best treatment and outcomes, and patient compliance and testing accuracy are key. Our GTT Gel addresses this need in a unique way that is superior to traditional approaches.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Hydrogels, Legal News Tagged With: Gelteq

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS